Thanks for the warm welcome Antibody. And apologies for the initial short post.
I follow MSB closely although I hold no stock. MSB are polarising. I find the differences between Collies and Roberts reports fascinating. I struggle with MSBs lack of reporting of preclinical and clinical data. I believe strongly that stem cells will be successful but doubt that one cell type will meet all the market needs.
The fresh verses frozen article is extremely relevant to MSB. Particularly to Prochymal as the study described is in graft verses host disease. It suggests that off-the-shelf stem cell products are going to need further development before they are successful. The cryopreservation methods haven’t changed for decades. Is MSB capable of overcoming these challenges? Not in-house their not. I don’t see reports of new technology or patents coming out of MSB. In my view, they should be aggressively acquiring technologies in this space.
- Forums
- ASX - By Stock
- fresh v frozen
Thanks for the warm welcome Antibody. And apologies for the...
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.07 |
Change
0.005(0.47%) |
Mkt cap ! $1.216B |
Open | High | Low | Value | Volume |
$1.08 | $1.10 | $1.06 | $3.371M | 3.135M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 45345 | $1.06 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.07 | 3875 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 858 | 1.095 |
1 | 57 | 1.085 |
4 | 59582 | 1.065 |
2 | 19133 | 1.060 |
2 | 14646 | 1.055 |
Price($) | Vol. | No. |
---|---|---|
1.015 | 8653 | 1 |
1.040 | 2014 | 1 |
1.045 | 2046 | 3 |
1.060 | 2120 | 2 |
1.065 | 53348 | 3 |
Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |